4
MEDICINSKI @URNAL
SADR@AJ - CONTENTS
VOLUMEN/VOLUME 14 - BROJ/NUMBER 1-2 2008
Izdava~ - Publisher KLINI^KI CENTAR UNIVERZITETA U SARAJEVU I
INSTITUT ZA NAU^NOISTRA@IVA^KI RAD I RAZVOJ Bolni~ka 25, Sarajevo,
Bosna i Hercegovina Za izdava~a Faris Gavrankapetanovi}, generalni
direktor KCUS
NAU^NI ^LANCI/ORIGINAL ARTICLEROSIGLITAZONE AND METFORMIN
TREATMENT IN DIABETICS WITH METABOLIC SYNDROME
..................................................5Zelija
Velija-Aimi, Beir Helji, Zoran Hrisafovi
Uredni{tvo - Editorial board Dili} Mirza glavni i odgovorni
urednik - editor in cheef
EFFECTS OF PREGNANCY ORDER ON THE ANTHROPOMETRIC PROPERTIES OF
THE NEWBORNS IN TUZLA REGION
........................................9 (BOSNIA
&HERZEGOVINA)Igor Hudi, Amira Redi, Mustafa Bainovi, Jasminka
Hadihalilovi, Zlatan Fatui
Dinarevi} Senka, Dizdarevi} Kemal Duri} Amira, Gerc Vjekoslav,
Helji} Be}ir Jadri}-Winterhalter Mira, Ku~ukali} Abdulah Lincender
Lidija, Mehi} Bakir, Obrali} Nermina Oru~ Lilijana, Radovi}
Svjetlana, Ra{i} Senija Koprivica Jelena, Redi} Amira @uti} Hasan,
generalni sekretar Izdava~ki savjet Publisher*s Advisory Board
Gavrankapetanovi} Ismet, predsjednik Dalagija Faruk, Dizdarevi}
Jadranka Duri} Osman, Gribaj~evi} Mehmed Hara~i} Midhat, Kosori}
Dragan, Loga Slobodan, Puva~i} Zlatko, Selak Ivan, [i{i} Fuad,
Trnini} Slobodan, Kudumovi} Mensura Lektor za engleski jezik
English language revision Bi~ak~i} Vera Lektor za Bosanski jezik
Bosnian language revision Boguni} Zineta Svi radovi i
korespondencija se upu}uju na adresu: All paper works and
correspondence should be adressed to: Bolni~ka 25, 71000 Sarajevo
Glavni urednik - Editor in chief Tel: 442-807 Tehni~ki sekretar -
Technical Secretary Tel: 668-415, 266-650, lok. 7884, 7264, Fax:
668-415 E-mail: [email protected] [tampa - Printed by BLICDRUK
Sarajevo [tampano u 250 primjeraka Printed in 250 samples Tehni~ki
urednik - Technical editor Blicdruk studio Za {tampariju - for
press Muhamed Hrlovi} MEDICINSKI @URNAL izlazi ~etiri puta godi{nje
MEDICAL JOURNAL Is published four times a year @iro ra~un - bank
account 129-101-10000878-52 Central Profit Banka DD Sarajevo,
Klini~ki centar Univerziteta (za Medicinski @urnal - Institut za
NIR) ISSN 1512-5866 www.mednal.com
KORELACIJA STANDARDNOG I COCKROFT-GAULT KREATININ KLIRENSA
CORRELATION OF STANDARD AND COCKROFT-GAULT CREATININE CLEARANCE
..........................................................................14Damir
ei, Rek Belagi, Senija Rai, Halima Resi, Amra Mataradija, Emir
Avdi, Jozo ori, Miralem Musi
TUBERKULOZA U FEDERACIJI BOSNE I HERCEGOVINE U PERIODU
1998.-2005. TUBERCULOSIS IN FEDERATION BOSNIA AND HERZEGOVINA
DURING PERIOD
1998-2005................................................19Hasan
uti, Bakir Mehi, Zehra Dizdarevi, Zlatan Hadimurtezi, Sabina
Krsmanovi, Aida Ustamuji, Jasminka Maglajli-Abduzaimovi, Jasmina
Mornjakovi
STRU^NI ^LANCI/PROFESSIONAL ARTICLEEPIDURALNA INJEKCIJA
KORTIKOSTEROIDA U TERAPIJI RADIKULARNE BOLI (RB) EPIDURAL STEROID
INJECTION IN THE TREATMENT OF RADICULAR
PAIN.......................................................................................24Sanela
Vesni, Suad Jaganjac, Vesna Sarajli, Edin Herceglija
INTERVENCIJE NA ARTERIJI FEMORALIS SUPERFICIALIS (AFS)
SUPERFICIAL FEMORAL ARTERY (SFA) INTERVENTION
.................................28Vesna Sarajli, Suad Jaganjac,
Sanela Vesni, Edin Herceglija, Aladin arovac, Deniz Bulja, Mirza
Dili, Emir Solakovi
PIGEONS OF THE CITY OF SARAJEVO RESERVOIRS AND CARRIERS OF
ZOONOSIS IN
HUMANS...........................................................32Emina
Reidbegovi, Aida Kavazovi, Jasminka Maglajli Abduzaimovi, Zehra
Dizdarevi, Sajma Dautovi - Krki, Amra Hadimuratovi - ustovi, Darja
Kese, Alenka Dovc
PRISTUPANOST KUPATILA ZA OSOBE S CEREBRALNOM PARALIZOM BATHROOM
ACCESSIBILITY FOR PERSONS WITH CEREBRAL
PALSY......................................................................................38Emira
vraka
5PREGLEDNI ^ANCI/REVIEW ARTICLEULOGA REACTIVE OXYGEN SPECIES NA
FOTOSTARENJE KOE I TRETMAN LOKALNIM ANTIOKSIDANSIMA ROLES OF
REACTIVE OXIGEN SPECIES IN PHOTOAGING PROCESS AND TOPICAL TREATMENT
WITH ANTIOXIDANTS.......................43Tanja Knor
PRIKAZ SLU^AJA/CASE REPORTGENTAMICIN NEPHROTOXICITY AT THE
DIABETIC PATIENT......................49Slaana Aneli
STREPTOKOKNI TOKSINI OK SINDROM UDRUEN SA NEKROTIZIRAJUIM
FASCITISOM STREPTOCOCCAL TOXIC SHOCK SINDROME ASSOCIATED WITH
NECROTIZIN
FASCITIS........................................................................51Nada
Koluder, Nermina Bajramovi, Edib Jerlagi, Enra Lukovac, Amra
Adrovi, Dalma Gagula, Abdulah Fazli, Rifet Gojak
AN ACUTE PSYCHOSIS ASSOCIATED TO A MILD FORM OF HEPATITIS A
................................................................................................56Sajma
Dautovi-Krki, Habiba Hasanagi-Rahi, Anita Mesi
KOMBINIRANI TRETMAN KORALIFORMNE UROLITIJAZE COMBINED TREATMENT
OF STAGHORN UROLITHIASIS..............................59Delaludin
Junuzovi, Zahid Lepara, Senad Bajramovi, Osman Hadiosmanovi
PRIKAZ KNJIGE/BOOK REVIEWMIKROSKOPSKE I FOTOGRAFSKE TEHNIKE
..................................................64Prikaz dao
Faris Gavrankapetanovi
INFORMACIJE/INFORMATION
....................................................66 UPUTSTVA
AUTORIMA MEDICINSKOG @URNALA
...............................................................................................67
Medicinski `urnal 2007 14 (1-2)
Nauni lanak / Original article
7
ROSIGLITAZONE AND METFORMIN TREATMENT IN DIABETICS WITH
METABOLIC SYNDROMEZelija Velija-Aimi*, Beir Helji, Zoran Hrisafovi
Clinic for Endocrinology, Diabetes and Metabolism Diseases,
Clinical Center, University of Sarajevo, Bolnika 25, 71000
Sarajevo, Bosnia and Herzegovina. * Corresponding author
SUMMARY The aim of our study was to evaluate the metformin and
rosiglitazone effects on glicoregulation and lipid concentration in
diabetics with metabolic syndrome. Study included 19 diabetics type
2 with metabolic syndrome (14 male/ 5 female, age-range 39-56
years, BMI range 27-38kg/ m2), who had previously been treated with
metformin. All patients were treated with combination of metformin
plus rosiglitazone for 3 months. Glicoregulation was evaluated
measuring fast blood glucose, postprandial blood glucose, HbA1c,
basal insulin, basal C-peptide and postprandial insulin. We
measured lipids level before and after treatment. Percentage,
average and standard deviation have been utilized in statistical
analysis. For three months of the treatment, HbA1c decreased for
1.6% (6.7+/-0.7% vs. 8.3+/-0.6, p5.6 mmol/L, or previously
diagnosed type 2 diabetes. If value is above 5.6 mmol/L, oral
glucose tolerance test is strongly recommended but is not necessary
to dene the presence of the syndrome. Other important signs and
clinical ndings supporting the diagnosis include: family component:
rst-degree relative with type 2 diabetes; Obesity: body-mass-index
(BMI) >30 kg/m2; abnormal glucose tolerance test result:
impaired glucose tolerance (IGT) or type 2 diabetes according to
World Health Organization [WHO] criteria; hyperuricaemia: fasting
serum urate >450 mol/L in men, >340 mol/L in women;
Microalbuminuria: urine albumin >20 mg/24 hours;
Hyperinsulinaemia: fasting plasma insulin >78 pmol/L (>13.0
mU/L); Alzheimers disease, depression, and sleep apnoea may also be
associated with metabolic syndrome. The aim of our study was to
evaluate the effect on glicoregulation and lipid concentration of
the combination of metformin plus rosiglitazone in diabetics with
metabolic syndrome. Trial design and subjects Study included 19
diabetic patients type 2 with metabolic syndrome (14 male/ 5
female, age-range 39-56 years, BMI range 27-38kg/m2), who had
previously been treated with metformin (table 1.). All patients
treated with combination of metformin plus rosiglitazone for 3
months. Glicoregulation was evaluated by measuring fast blood
glucose (FBG), postprandial blood glucose (PBG), HbA1c, basal
insulin, basal C-peptide and postprandial insulin. We measured
level of lipids (total cholesterol, LDL, VLDL, HDL, triglycerides)
before and after combination treatment. Percentage, average and
standard deviation have been utilized in statistical analysis.Table
1. Baseline characteristics
Medicinski `urnal 2008 14 (1-2): 5-7
Zelija Velija-Aimi, Beir Helji, Zoran Hrisafovi. Rosiglitazone
and metformin treatment in diabetics with metabolic syndrome
8RESULTS For three months of the treatment, HbA1c decreased for
1.6% (6.7+/-0.7% vs. 8.3+/-0.6, p
